Multicenter evaluation of the quidel lyra direct C. difficile nucleic acid amplification assay

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 1998-2002

  Beck, Eric T ^a   Buchan, Blake W ^a,b   Riebe, Katherine M ^a   Alkins, Brenda R ^d   Pancholi, Preeti ^c   Granato, Paul A ^d   Ledeboera, Nathan A ^b  

^a DYNACARE LABORATORIES   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Laboratory Alliance of Central New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASSAY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CALIBRATION; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CULTURE MEDIUM; CULTURE TECHNIQUE; FECES ANALYSIS; HUMAN; INTERMETHOD COMPARISON; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; COMPARATIVE STUDY; DIARRHEA; EVALUATION STUDY; FECES; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; PROSPECTIVE STUDY; SERODIAGNOSIS; UNITED STATES;

BACTERIAL TOXIN;

BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FECES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEUTRALIZATION TESTS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84901650235     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03089-13     Document Type: Article

References (24)

1. Stevens DL, Bryant AE, Berger A, von Eichel-Streiber C. 2011. Clostridium, p 834-857. In Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, WarnockDW(ed), Manual of clinical microbiology, 10th ed, vol 1. ASM Press, Washington, DC.
2. Elixhauser A, Jhung M. 2008. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005.Healthcare Cost and Unitization Project. Statistical brief no. 50. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.pdf.
3. Kyne L, Hamel MB, Polavaram R, Kelly CP. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353. http://dx.doi.org/10.1086/338260. (Pubitemid 34062235)
4. Bouza E. 2012. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin. Microbiol. Infect. 18(Suppl 6):5-12. http://dx.doi.org/10.1111/1469-0691.12064.
5. Badger VO, Ledeboer NA, Graham MB, Edmiston CE, Jr. 2012. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. J. Parenter. Enteral. Nutr. 36:645-662. http://dx.doi.org/10.1177/0148607112446703.
6. Barbut T, Surgers L, Eckert C, Visseaux B, Cuingnet M, Mesquita C, Pradier N, Thiriez A, Ait-Ammar N, Aifaoui A, Grandsire E, Lalande V.March 2013. Does a rapid diagnosis of Clostridium difficile infection impact quality of patient management? Clin. Microbiol. Infect. http://dx.doi.org/10.1111/1469- 0691.12221.
7. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455. http://dx.doi.org/10.1086/651706.
8. Massey V, Gregson DB, Chagla AG, Storey M, John MA, Hussain Z. 2003. Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. Am. J. Clin. Pathol. 119:45-49. http://dx.doi.org/10.1309/U8ATL52Q60XYAVX6. (Pubitemid 37047895)
9. Vanpoucke H, De BT, Claeys G, Vaneechoutte M, Verschraegen G. 2001. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin. Microbiol. Infect. 7:55-64. http://dx.doi.org/10.1046/j.1469-0691.2001.00141.x. (Pubitemid 34960272)
10. Wilcox MH. 2012. Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin. Microbiol. Infect. 18(Suppl 6):13-20. http://dx.doi.org/10.1111/1469-0691.12057.
11. Buchan BW, Mackey TA, Daly JA, Alger G, Deny GA, Peterson LR, Kehl SC, Ledeboer NA. 2012. Multicenter clinical evaluation of the Portrait Toxigenic C. difficile Assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J. Clin. Microbiol. 50:3932-3936. http://dx.doi.org/ 10.1128/JCM.02083-12.
12. Carroll KC. 2011. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe 17:170-174. http://dx.doi.org/10.1016/ j.anaerobe.2011.01.002.
13. Belanger SD, Boissinot M, Clarioux N, Picard FJ, Bergeron MG. 2003. Rapid detection of Clostridium difficile in feces by real-time PCR. J. Clin. Microbiol. 41:730-734. http://dx.doi.org/10.1128/JCM.41.2.730-734.2003. (Pubitemid 36184188)
14. Newcombe RG. 1998. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17:857-872. http://dx.doi.org/10.1002/(SICI)1097-0258(19980430)17:8-857::AID-SIM777-3.0. CO;2-E. (Pubitemid 28185165)
15. McNemar Q. 1947. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 12:153-157. http://dx.doi.org/10.1007/BF02295996.
16. Stuart A. 1955. A test for homogeneity of the marginal distributions in a two-way classification. Biometrika 42:412-416. http://dx.doi.org/10.1093/ biomet/42.3-4.412.
17. Stamper PD, Alcabasa R, Aird D, Babiker W, Wehrlin J, Ikpeama I, Carroll KC. 2009. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J. Clin. Microbiol. 47:373-378. http://dx.doi.org/10.1128/JCM.01613-08.
18. Stamper PD, Babiker W, Alcabasa R, Aird D, Wehrlin J, Ikpeama I, Gluck L, Carroll KC. 2009. Evaluation of a new commercial TaqMan PCR assay for direct detection of the Clostridium difficile toxin B gene in clinical stool specimens. J. Clin. Microbiol. 47:3846-3850. http://dx.doi.org/10.1128/JCM.01490-09.
19. Novak-Weekley SM, Marlowe EM, Miller JM, Cumpio J, Nomura JH, Vance PH, Weissfeld A. 2010. Clostridium difficile testing in the clinical laboratory by use of multiple testing algorithms. J. Clin. Microbiol. 48: 889-893. http://dx.doi.org/10.1128/JCM.01801-09.
20. Noren T, Alriksson I, Andersson J, Akerlund T, Unemo M. 2011. Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J. Clin. Microbiol. 49:710-711. http://dx.doi.org/10.1128/JCM.01824-10.
21. Hicke B, Pasko C, Groves B, Ager E, Corpuz M, Frech G, Munns D, Smith W, Warcup A, Denys G, Ledeboer NA, Lindsey W, Owen C, Rea L, Jenison R. 2012. Automated detection of toxigenic Clostridium difficile in clinical samples: isothermal tcdB amplification coupled to array-based detection. J. Clin. Microbiol. 50:2681-2687. http://dx.doi.org/10.1128/JCM.00621-12.
22. Le Guern R, Herwegh S, Grandbastien B, Courcol R, Wallet F. 2012. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J. Clin. Microbiol. 50:3089. http://dx.doi.org/10.1128/JCM.01250-12.
23. Pancholi P, Kelly C, Raczkowski M, Balada-Llasat JM. 2012. Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays. J. Clin. Microbiol. 50:1331-1335. http://dx.doi.org/10.1128/JCM.06597-11.
24. Viala C, Le MA, Maataoui N, Rousseau C, Collignon A, Poilane I. 2012. Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile. J. Microbiol. Methods 90:83-85. http://dx.doi.org/10.1016/j.mimet. 2012.04.017.